# Processa Pharmaceuticals, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Processa Pharmaceuticals, Inc.). ## Overview Processa Pharmaceuticals, Inc. is a U.S.-based clinical-stage biopharmaceutical company developing small-molecule drug candidates for cancer and other therapeutic areas. Its pipeline includes next-generation oncology programs such as NGC-Cap, NGC-Gem, and NGC-Iri, along with two non-oncology candidates that may be pursued through partnering or licensing. ## Products & services • NGC-Cap (PCS6422) oncology drug candidate • NGC-Gem (PCS3117) oncology drug candidate • NGC-Iri (PCS11T) oncology drug candidate • PCS12852 non-oncology drug candidate • PCS499 non-oncology drug candidate • Clinical development and regulatory science approach - **Oncology pipeline** (0%) — Small-molecule cancer therapy candidates designed to improve efficacy and reduce toxicity. - **Non-oncology pipeline** (0%) — Additional drug candidates outside oncology that may be advanced or partnered. - **Drug development services** (100%) — Internal research, preclinical work, and clinical trial execution for company-owned assets. - NGC-Cap (PCS6422) oncology drug candidate - NGC-Gem (PCS3117) oncology drug candidate - NGC-Iri (PCS11T) oncology drug candidate - PCS12852 non-oncology drug candidate - PCS499 non-oncology drug candidate - Clinical development and regulatory science approach ## Customers Processa does not currently sell approved products; its economic counterparties are primarily clinical research organizations, research institutions, investigators, regulators, and potential licensing or collaboration partners. If its programs succeed, the end customers would be oncology patients and the physicians and hospitals that prescribe or administer the therapies. - **Clinical research organizations and trial sites** (primary) — They perform and manage preclinical studies and clinical trials for Processa's drug candidates. - **Research institutions** (primary) — They provide scientific services, testing, and study execution support for development programs. - **Potential licensing and collaboration partners** (secondary) — They may acquire rights to non-oncology assets or co-develop programs to share risk and funding. - **Future oncology prescribers and patients** (emerging) — They would use approved therapies if the company's oncology candidates reach commercialization. - CROs and research institutions conducting preclinical and clinical studies - Clinical investigators and trial sites enrolling patients - Potential licensing or partnership counterparties for non-oncology assets - Future oncologists, hospitals, and patients if candidates are approved - Regulators and ethics committees that govern development milestones ## Geography Processa is headquartered in the United States and its development, financing, and regulatory activities are centered there. Its clinical and regulatory exposure is primarily U.S.-based, although drug development and eventual commercialization could involve foreign trial sites, partners, or markets. - United States is the core operating and financing base - FDA oversight is central to development and approval risk - Clinical trial activity may involve U.S. and foreign sites - Future commercialization would depend on approved market geographies - No country-level revenue is disclosed because no products are approved ## Strategy The company is focused on advancing a small pipeline of next-generation cancer therapies using a regulatory science approach intended to improve the odds of approval. It also evaluates non-oncology assets for out-licensing or partnership, which can help fund development while preserving value in the portfolio. - **Advance NGC-Cap and other oncology candidates through clinical development** (short-term) — Clinical data is the main value driver for a biopharma pipeline and determines future partnering or approval potential. - **Use regulatory science to improve approval probability** (medium-term) — A clearer regulatory path can reduce development risk and improve the attractiveness of the assets to partners. - **Monetize non-oncology assets through partnering** (medium-term) — Out-licensing can create non-dilutive funding and reduce the need to carry every program internally. - Advance oncology candidates through clinical proof-of-concept - Use a regulatory science approach to support approval strategy - Prioritize programs with known mechanisms and toxicity issues - Seek partnerships or out-licensing for non-oncology assets - Raise external capital to fund trials and development work ## Risks The company faces the core risks of clinical-stage drug development: trial failure, safety issues, regulatory delays, and the possibility that programs are terminated before commercialization. It also depends on external financing, so dilution, unfavorable deal terms, or inability to raise capital could constrain development and threaten the pipeline. - **Clinical development failure** [critical] — Drug candidates can be halted if scientific progress is insufficient or results are not commercially viable. - **Regulatory delay or non-approval** [high] — FDA and other agencies can delay, request more data, or reject applications, extending timelines and costs. - **Financing and dilution risk** [high] — The company depends on equity, debt, or partnering to fund operations until commercialization. - **Clinical trial execution and accrual estimation risk** [medium] — Trial costs depend on enrollment, site activity, and third-party performance, which can differ from estimates. - **Nasdaq listing compliance risk** [medium] — Failure to meet exchange requirements could reduce liquidity and access to capital. - Clinical trials may fail to show efficacy or acceptable safety - FDA review delays can slow or block development and approval - Funding shortfalls can force program delays, reductions, or suspension - Dependence on CROs and investigators creates execution and cost-estimate risk - Nasdaq listing compliance and capital markets access remain important ## Accounting As a clinical-stage biopharma, Processa expenses research and development as incurred, so trial timing and vendor estimates can materially affect quarterly results. Clinical trial accruals rely on estimates of patient enrollment, site activity, and CRO services, while prepaid research costs are recognized as services are delivered. - **Clinical trial accrual estimates** — Quarterly R&D comparability - **Preclinical and clinical prepaid expenses** — Balance sheet and period expense timing - **Going-concern and financing dependence** — Liquidity presentation and investor assessment - R&D is expensed as incurred, driving losses before any product revenue - Clinical trial accruals depend on enrollment and third-party service estimates - Prepaid trial costs are expensed when services are rendered - No product revenue is recognized because no candidates are approved - Future licensing or collaboration deals could create milestone or deferred revenue complexity --- *Last updated: 2026-04-29T04:49:44.889305+00:00*